Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
JAGSNPHARM Stock Analysis
Views
Red Flags
Positive
High and improving ROE
High and stable operating margin
Low Debt to Equity, not much change from last year
Company is net cash
Negative
Expensive and at same valuation levels as industry median P/E
Weak price momentum
Low EPS growth and lower than median growth of industry
Neutral
Moderate revenue growth and in line with median growth of industry
Company's earnings are of moderate quality
Moderate dividend yield
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
JAGSNPHARM Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
JAGSNPHARM Bulk, Block & Insider Trades
JAGSNPHARM Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Stock split
Others
Stock split(1 : 3)Nominal Value change from INR 05 INR 02. Ex-date: 8th Jan 2025 Announced on: 23rd Oct 2024
Complex capital changeThe company has decided to issue bonus share in the ratio of 3:1 i.e.three bonus shares of Rs.5 each for every one equity share of Rs.5 each. Ex-date: 20th Jul 2004 Announced on: 17th Jun 2004
Company Profile
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yulipris... Read More
Key personnel
Mr. Rajpal Singh KochharD
Chairman of the Board, Managing Director
Mr. Nirav Niranjankumar Vora
Chief Financial Officer
Mr. Amrut Medhekar
Chief Operating Officer
Mr. Pratham Rawal
Compliance Officer, Company Secretary
Mr. Manish GuptaD
Managing Director, Additional Director
Mr. Prithipal Singh KochharD
Non-Executive Additional Director
Mr. Harsha RaghavanD
Non- Executive Additional Director
Ms. Radhika Madhukar DudhatD
Non-Executive Additional Independent Director
View all
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Website
Phone no.
Address
Frequently Asked Questions about JAGSNPHARM
What is the current share price of Jagsonpal Pharmaceuticals Ltd.?
The current share price of Jagsonpal Pharmaceuticals Ltd. is ₹ 172.82 as of 24 Feb 2026.
What is the PE ratio of Jagsonpal Pharmaceuticals Ltd.?
The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd. is 28.26 as of the latest financial data.
What is the ROE and ROCE of Jagsonpal Pharmaceuticals Ltd.?
Jagsonpal Pharmaceuticals Ltd. has a Return on Equity (ROE) of 27.53% and a Return on Capital Employed (ROCE) of 19.52% as per the latest financial reports.
What is the market cap of Jagsonpal Pharmaceuticals Ltd.?
The market capitalization of Jagsonpal Pharmaceuticals Ltd. stands at ₹ 1,155.99 Cr.
What is the dividend yield of Jagsonpal Pharmaceuticals Ltd.?
The dividend yield of Jagsonpal Pharmaceuticals Ltd. is 1.45% based on the current market price.
What is the RSI of Jagsonpal Pharmaceuticals Ltd.?
The Relative Strength Index (RSI) of Jagsonpal Pharmaceuticals Ltd. is 45.13.
What is the FII and DII holding in Jagsonpal Pharmaceuticals Ltd.?
Foreign Institutional Investors (FII) hold 2.12% and Domestic Institutional Investors (DII) hold 0.00% of Jagsonpal Pharmaceuticals Ltd. shares.
What sector does Jagsonpal Pharmaceuticals Ltd. belong to?
Jagsonpal Pharmaceuticals Ltd. operates in the Healthcare sector.
What is the beta of Jagsonpal Pharmaceuticals Ltd. stock?
The beta of Jagsonpal Pharmaceuticals Ltd. stock is 1.34, indicating its volatility relative to the broader market.
